Form 4: Aurinia Pharmaceuticals Director, Craig Johnson, Granted Stock Options

Director Craig Johnson of Aurinia Pharmaceuticals Inc. was granted stock options on May 16, 2025, exercisable for 37,485 common shares.

Summary

• Craig Johnson, a director of Aurinia Pharmaceuticals Inc., was granted stock options on May 16, 2025.
• The options allow Johnson to purchase 37,485 common shares of Aurinia at an exercise price of $8.15 per share.
• The options vest one year from the grant date and expire ten years from the grant date, on May 16, 2035.
• Johnson directly owns 37,485 derivative securities following the reported transaction.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as the granting of stock options is a common practice and aligns the director's interests with shareholders.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards increasing the company's value.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Gilead Sciences and Amgen also use stock options to incentivize their directors and officers.
• The vesting schedule of one year is fairly typical for these types of grants.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to increase the company's value.

Key Dates

Keywords

stock options, director, Aurinia Pharmaceuticals, AUPH, Craig Johnson, beneficial ownership, Form 4